Skip to content
Homepage
Author:
uniQure Inc.
Posted Date:
July 29, 2026
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
uniQure Inc.
July 29, 2026
uniQure to Announce Second Quarter 2026 Financial Results
uniQure Inc.
July 22, 2026
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure Inc.
June 25, 2026
uniQure Announces Pricing of Upsized $225 Million Public Offering
uniQure Inc.
June 23, 2026
uniQure Announces $150 Million Proposed Public Offering
uniQure Inc.
June 22, 2026
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure Inc.
June 19, 2026
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
uniQure Inc.
June 17, 2026
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
uniQure Inc.
May 5, 2026
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
uniQure Inc.
April 30, 2026
uniQure to Announce First Quarter 2026 Financial Results
uniQure Inc.
April 28, 2026
1
2
Next
